Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
05/06/2024 | 12:04 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VIR | Vir Biotechnology Inc |
05/06/2024 | 11:30 | Business Wire | Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment | NASDAQ:VIR | Vir Biotechnology Inc |
03/06/2024 | 18:13 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VIR | Vir Biotechnology Inc |
03/06/2024 | 17:57 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:VIR | Vir Biotechnology Inc |
29/05/2024 | 22:05 | Business Wire | Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference | NASDAQ:VIR | Vir Biotechnology Inc |
29/05/2024 | 14:05 | Business Wire | Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer | NASDAQ:VIR | Vir Biotechnology Inc |
23/05/2024 | 22:05 | Business Wire | Vir Biotechnology to Host 2024 Annual Meeting of Stockholders | NASDAQ:VIR | Vir Biotechnology Inc |
22/05/2024 | 14:05 | Business Wire | Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 | NASDAQ:VIR | Vir Biotechnology Inc |
21/05/2024 | 14:17 | Business Wire | Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024 | NASDAQ:VIR | Vir Biotechnology Inc |
14/05/2024 | 22:05 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:VIR | Vir Biotechnology Inc |
02/05/2024 | 22:05 | Business Wire | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | NASDAQ:VIR | Vir Biotechnology Inc |
30/04/2024 | 22:05 | Business Wire | Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 | NASDAQ:VIR | Vir Biotechnology Inc |
18/04/2024 | 14:00 | Business Wire | Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors | NASDAQ:VIR | Vir Biotechnology Inc |
11/04/2024 | 22:30 | Business Wire | Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 | NASDAQ:VIR | Vir Biotechnology Inc |
05/03/2024 | 14:05 | Business Wire | Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule | NASDAQ:VIR | Vir Biotechnology Inc |
26/02/2024 | 22:27 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:VIR | Vir Biotechnology Inc |
26/02/2024 | 22:10 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:VIR | Vir Biotechnology Inc |
23/02/2024 | 14:05 | Business Wire | Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences | NASDAQ:VIR | Vir Biotechnology Inc |
22/02/2024 | 22:05 | Business Wire | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:VIR | Vir Biotechnology Inc |
20/02/2024 | 22:30 | Business Wire | Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer | NASDAQ:VIR | Vir Biotechnology Inc |
13/02/2024 | 23:00 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:VIR | Vir Biotechnology Inc |
01/02/2024 | 22:05 | Business Wire | Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024 | NASDAQ:VIR | Vir Biotechnology Inc |
14/12/2023 | 11:59 | IH Market News | Apple Stocks Reach Record, Adobe Faces Stock Drops, Berkshire Hathaway Increases Stake in OXY, and More | NASDAQ:VIR | Vir Biotechnology Inc |
13/12/2023 | 22:05 | Business Wire | Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation | NASDAQ:VIR | Vir Biotechnology Inc |
06/12/2023 | 22:05 | Business Wire | Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference | NASDAQ:VIR | Vir Biotechnology Inc |
13/11/2023 | 14:00 | Business Wire | Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023 | NASDAQ:VIR | Vir Biotechnology Inc |
10/11/2023 | 14:00 | Business Wire | Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023 | NASDAQ:VIR | Vir Biotechnology Inc |
08/11/2023 | 14:05 | Business Wire | Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™ | NASDAQ:VIR | Vir Biotechnology Inc |
03/11/2023 | 21:33 | Edgar (US Regulatory) | Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers | NASDAQ:VIR | Vir Biotechnology Inc |
03/11/2023 | 21:05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:VIR | Vir Biotechnology Inc |